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1. Introduction 
The challenge to comprehend the physiology as well as cell biology of the blood-brain 
barrier (BBB) began with Ehrlich and Goldman’s experimental observations that the central 
nervous system (CNS) is not stained by intravascular vital dyes. These studies provided the 
first evidence of the presence of an obstructing barrier between blood and brain. Later on, 
researchers like Friedemann (1942) used basic highly lipid soluble dyes to cross the BBB in 
order to show the brain penetration of the dyes by direct transport across the cerebral 
microvasculature. In 1941, Broman presented his observations upon the existence of two 
different barrier systems within the brain: the BBB at the cerebral microvasculature, and the 
blood-CSF barrier at the choroid plexus. It is now clear that in fact three main barrier layers 
at the interface between blood and tissue protect the CNS: the endothelium of brain 
capillaries, and the epithelia of the choroid plexus (CP) and the arachnoid (Abbott, 2005; 
Engelhardt, 2006). 
In 1941, Broman proposed that it was the cerebral capillary endothelial cells that contribute 
the physical barrier function of the BBB, and not the astrocytic end feet. The argument 
concerning whether the astrocytes or the capillary endothelium constitute the BBB was 
supported by electron microscopic cytochemical studies performed in 1967 by Reese and 
Karnovsky. They used horseradish peroxidase (HRP), ~40 kDa, to visualize the BBB by 
systemic injections of HRP which failed to reach the brain extracellular fluid, whereas 
intracerebroventricular injection into the CSF stained the brain extracellular fluid positive 
for HRP (Reese & Karnovsky, 1967).  
It is now evident that the BBB is a unique membranous barrier, which restrictively isolates 
the brain parenchyma from the circulating molecules/compounds within the blood. The 
permeability of BBB is regulated by transport machineries of the brain capillary endothelial 
cells that are modulated by autocrine and paracrine secretions from several types of cells, 
such as the pericyte, the astrocyte, and neurons (Rubin & Staddon, 1999).  
The pericyte cells share the capillary basement membrane with the endothelium and 
physically supports endothelial cells (Allt & Lawrenson, 2001). It has been revealed that 
there is approximately one pericyte for every three endothelial cells (Pardridge, 1999). It is 
deemed that the pericyte cells play a regulatory role in brain angiogenesis, endothelial cell 
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tight junction formation, BBB differentiation, and also contribute to the microvascular 
vasodynamic capacity and structural stability.  
The astrocyte cells invest approximately 99% of the abluminal surface of the brain capillary 
and induce endothelial cells to differentiate directly through cell to cell communication or 
indirectly by secreting astrocytic factors (Pardridge, 1999). Brain capillary endothelial cells 
display different features in comparison with peripheral endothelial cells. The BBB can be 
thought of brain capillary endothelial cells (BCECs) with the physical and paracrine 
interactions between the endothelial cells (ECs), the pericyte, and the astrocyte (Abbott et al., 
2006; Pardridge, 1999). 
The ability of BCECs to form a restrictive barrier between blood and brain is not completely 
intrinsic to the brain microvascular endothelial cells, but instead is induced by the brain 
environment itself. Induction of BBB may be categorized as "directive" and "impremissive" 
events. The latter term means that the inductor functions upon a tissue that is already 
determined toward its final fate but still needs an exogenous stimulus for the expression of 
its full phenotype. Of note, with the lack of a brain neuronal environment, the selective 
restrictiveness characteristics of the BCECs disappear, and as a result appropriate 
incitement(s) ought to be continuous at the BBB microenvironment to maintain its 
functionalities (Abbott, 2005).  
The astrocyte inductive effects upon endothelial cell differentiation have been examined by 
Stewart & Wiley (1981). They transplanted avascular tissue from 3-day-old quail brain into 
the coelomic cavity of chick embryos, the chick endothelial cells then vascularized the quail 
brain grafts formed a competent BBB. In contrast preformed microvessels growing in 
embryonic quail muscle, which were implanted in chick brain were leaky and lacked BBB 
enzymes (Stewart & Wiley, 1981).  
With regard to the complexity of the BBB, basically, other differentiating factors apart from 
astrocytes may play a role on the formation of the BBB. However, we discuss the most 
important features of BBB in relation to drug delivery and targeting for brain tumors. Fig. 1 
represents the schematic illustration of BCECs.  
2. BBB junctional complexes and cell-to-cell interactions  
Stable cell-to-cell interactions are required to keep the structural integrity of tissues. Dynamic 
changes in cell-to-cell adhesion will participate in the morphogenesis of developing tissues. 
Adhesion mechanisms are highly regulated during tissue morphogenesis and related to the 
processes of cell motility and cell migration. Cell junctions, basically, can be classified into 
three functional groups, including: 1) tight junctions (TJs), 2) anchoring (adherent) junctions 
(AJs), and 3) gap (communication) junctions (GJs). Of these junctions, the TJs seal cells together 
in cell sheet, the AJs attach cells to their neighbors or to the extra-cellular matrix mechanically, 
and the GJs mediate the passage of chemicals or electrical signals from one interacting cell to 
its partner (Engelhardt, 2006; Omidi & Gumbleton, 2005). Because of crucial role of TJs in 
restrictive function of BBB, they are briefly discussed.  
Fig. 2 shows the diagrammatic representation of TJs and its complexity with other proteins 
at the BBB. TJs of the BBB generate a rate-limiting restrictive barrier to paracellular diffusion 
of solutes between endothelial cells. They are the most apical element of the junctional 
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complex that includes both tight and adherens junctions. In terms of morphology, TJs form a 
continuous network of parallel, interconnected, intra-membrane strand of various proteins 
arranged as a series of multiple barriers.  
 
Fig. 1. Schematic demonstration of part of cortex and brain capillary endothelial cells. Star 
shape astrocytes are in communication with both brain capillaries and neurons via end-foot. 
The ultrastructural characteristics (in particular presence of tight junction) of the brain 
capillary endothelial cells differ them from other peripheral capillaries. Some of important 
specialized transporters are illustrated on luminal section which represents vesicular 
trafficking machineries for traverse necessary macromolecules from blood to brain, adapted 
with permission (Omidi & Barar, 2012).  
2.1 Tight junctions of BBB 
Using freeze–fracture technique, it has been shown that the tight junctions of the BBB are 
characterized by the highest complexity found in the vasculature, so that protoplasmic 
fracture face (P-face) association of the BBB compare to the peripheral endothelial cells is 
55% and 10%, respectively. The altered particles distribution implies the presence of a strong 
interaction between TJs of the BBB and cytoskeleton. TJs of the BBB, morphologically, are 
more comparable to TJs of the epithelial cells than to TJs of the endothelial cells in 
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peripheral blood vessels. Although the tight junction of BBB discloses many characteristics 
of epithelial TJs, there are distinctive differences between them, e.g. in terms of particle 
density and distribution, in relation to response to ambient factors.  
 
Fig. 2. Illustration of the brain capillary endothelial cells (BCECs) morphology and 
architecture. A) Schematic elongated two brain capillary endothelial cells with some apical 
transporters. B) Vesicular membrane of BCECs showing coated and uncoated vesicles.  
C) Transmission electron microscopy micrograph of BCECs showing tight junction (TJ).  
D) Tight junctional interactions of two endothelial cells. The TJ is embedded in a cholesterol-
enriched region of the plasma membrane. Claudins comprise a multigene family with 20 
isoforms currently identified and form the backbone of TJ strands by making dimers and 
binding homotypically to claudins on adjacent cells to produce the primary seal of the TJ. 
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Claudin 1, 3 and 5 are present at the BBB. Occludin functions as a dynamic regulatory 
protein causing increased electrical resistance across the membrane and decreased 
paracellular permeability. BBB endothelial cells in vivo reveal a P-face/E-face ratio of about 
55%/45%, and as claudin-3 and claudin-5 are well expressed, it can be suggested that the 
degree of association with one or the other leaflet roughly reflects the stoichiometry of 
claudin expression in the TJs of BBB. However, in the non-BBB endothelial cells, tight 
junctions are almost completely associated with the E-face and claudin-3 is rarely or not 
expressed, adapted with permission (Omidi & Barar, 2012).  
Many identified ubiquitous molecular components of junctional complexes in the epithelia 
such as claudins, occludins, zonula (ZO-1, ZO-2, ZO-3) , junctional adhesion molecules 
(JAMs), cingulin, and 7H6 have been detected at the BBB. Both tight and adherent junctions 
are composed of multiple protein complexes, which communicate with the actin 
cytoskeleton of the cells (Kniesel & Wolburg, 2000).  
The TJ contains various proteins, which are necessary to form structural support for the 
tight junction such as zonula occludens proteins that belong to a family of membrane 
associated guanylate kinase-like proteins and serve as recognition proteins for tight 
junctional placement and as a support structure for signal transduction proteins. Junctional 
adherent molecules (JAMs) are localized at the TJ and are members of the immunoglobin 
superfamily, which can function in association with platelet-endothelial cellular adhesion 
molecule 1 (PECAM1) to regulate leukocyte migration. Cingulin is a double-stranded 
myosin-like protein that binds preferentially to ZO proteins at the globular head and to 
other cingulin molecules at the globular tail. The primary cytoskeletal protein, actin, has 
known binding sites on all of the ZO proteins, and on claudin and occludin. 
In terms of TJ regulation, phosphorylation of both transmembrane and accessory proteins 
plays an important role in establishing and regulating the TJs. The Occludin and ZO1, as the 
primary regulatory proteins of the TJs, are phosphorylated on serine, threonine and tyrosine 
residues. The increased phosphorylation of serine/threonine correlates with decreased 
extractability of occludin and TJs assembly. Regulation of TJs is also dependent on tyrosine 
phosphorylation of proteins at cell to cell contacts. Development of TJ barrier functions has 
been correlated with decreased tyrosine phosphorylation of proteins at the TJ complexes. 
Protein kinase C (PKC) also is a major regulator of TJs formation and regulation. It plays an 
important role in ZO1 migration to the plasma membrane and there are PKC 
phosphorylation consensus sequences in the ZO1 protein, suggesting that ZO proteins serve 
as scaffolding for PKC signal transduction pathways on the cytoplasmic surface of 
intercellular junctions. It has also been shown that TJs are generally localized at cholesterol-
enriched regions or rafts within the plasma membrane. Caveolin-1, an integral protein 
within caveolae membrane domains may associate with TJ components. Caveolin-1 itself 
interacts with and regulates the activity of several signal transduction pathways and 
downstream targets. Several cytoplasmic signaling molecules are concentrated at TJ 
complexes and are involved in signaling cascades that control assembly and disassembly of 
TJs (Krizbai & Deli, 2003). 
The structure and function of TJs in primary cultures of bovine brain endothelial cells were 
directly analyzed, using quantitative freeze-fracture electron microscopy, and ion and inulin 
permeability (Wolburg et al., 1994), and it was shown that the cultured brain endothelial 
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cells tend to lose the TJ-dependent BBB characteristics such as macromolecular 
impermeability and high electrical resistance with conditioned culture. The tight junction 
complexity index (CI), as the number of branch points per unit length of tight junctional 
strands, was decreased 5 hr after culturing the primary bovine brain microvessel endothelial 
cells. However, the association of TJ particles with the cytoplasmic leaflet of the endothelial 
membrane bilayer (P-face) decreased steadily during culture with a major drop between 16 
hr and 24 hr. Wolburg et al. showed that the CI could be increased by elevation of 
intracellular cyclic adenosine monophosphate (cAMP) levels, while phorbol esters had the 
opposite effect - the endothelial cells P-face association of TJ particles was enhanced by 
elevation of cAMP levels and by astrocyte coculture (ACC) or exposure to astrocyte 
conditioned-medium (ACM). The authors also highlighted that astrocytes induced the latter 
effect on P-face association; and also showed that elevation of cAMP levels together with 
ACM increased trans-endothelial/epithelial electrical resistance (TEER) synergistically and 
decreased inulin permeability of primary cultures. They, thus, concluded that P-face 
association of TJ particles in brain ECs may be a critical feature of the blood-brain barrier 
functionality that can be specifically modulated by astrocytes and cAMP levels.  
2.2 Astrocytes  
Astrocytes are glial cells that envelop >99% of the BBB endothelium (Hawkins & Davis, 
2005). Astrocytes and endothelial cells reciprocally affect each other’s structure 
and/functions - their interactions induce and modulate the development of the BBB. Such 
interaction enhances the TJs and reduces the gap junctional area of BCECs, while increases 
the number of astrocytic membrane particle assemblies and astrocyte density. Astrocytes are 
essential for proper neuronal activities, for which the close proximity of astrocytes and 
BCECs appear to be essential for a functional neurovascular unit (Abbott et al., 2006). Based 
on in vitro investigations, the coculture of BCECs with astrocytes can improve the BBB 
functionality such as permeability and cellular transport functions (Omidi et al., 2008).  
The nature of the astrocyte-derived factors (ADFs) is not fully understood, inductive effect 
of ADFs on brain microvascular endothelial cell differentiation and BBB formation has been 
well reported. Investigation upon the modulatory effects of astrocyte on BCECs have 
revealed that the rat astrocyte cells are able to modulate the chick peripheral ECs to make 
them less permeable to large molecules. On the molecular level, increased expression of 
barrier-relevant proteins (e.g., tight junction proteins) has so far been documented in the 
presence of ADFs. Many studies have shown the improvement of physiological parameters 
(e.g., increased TEER and decreased paracellular permeability) in different in vitro models 
of the BBB treated with ADFs. Moreover, it should be evoked that the interaction of BCECs 
and astrocytes is bidirectional and that the other cell types surrounding the brain 
microvasculature also contribute to BBB function or dysfunction. From many kinds of 
different experimental designs, it is quite clear that astrocyte factors are able to modulate TJ 
restrictiveness under perhaps certain defined conditions. To test the astrocytic factors effect 
on endothelial cells, Shivers et al. (1988) aimed to find out whether these factors can initiate 
development of non-CNS microvessel endothelial cells by culturing and passaging bovine 
aorta and pulmonary artery endothelial cells in the presence of 50% ACM. The investigators 
reported the endothelial cells maintained in ACM displayed complex tight junctions as well 
as gap junctions, but the cells plated onto plastic or fibronectin-coated substrates without 
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ACM showed no tight or gap junctions. This finding directed them to conclude that CNS 
astrocytes generate soluble factor(s), which can provoke formation of tight junction 
components in non-CNS endothelial cells. Astrocyte inductive effect(s) on the expression of 
the BBB characteristic enzymes including Ǆ-glutamyl transpeptidase (Ǆ-GTP) and alkaline 
phosphatase  have been well presented (Allt & Lawrenson, 2001; Haseloff et al., 2005). Using 
an astrocyte coculture system with endothelial cells Rauh et al (1992) showed that a possible 
direct cell-to-cell contact between BCECs and astroglial cells is probably needed for 
astrocyte inductive effects. However this is a controversial issue as secreted ADF effects on 
endothelial cells are well recognized. Shivers et al (1988) and Tio et al. (1990) also reported 
that both ACC and ACM (isolated rat brain astrocyte cells) can induce the alkaline 
phosphatase activity and tight junction generation in the human umbilical cord vein 
endothelial cells (Shivers et al., 1988; Tio et al., 1990). 
In 1999, Igarashi et al. examined the relationship of glial-derived neurotrophic factor 
(GDNF), which maintains the dopaminergic system and motor neurons in vivo, with BBB 
using isolated primary porcine brain capillary endothelial cells (PBCECs) and reported that 
GDNF at concentrations of 0.1 and 1 ng per ml can significantly enhance the barrier 
functionality (tight junction integrity) with increases in TEER values and decreases in 
mannitol permeability (Igarashi et al. 1999). It can be deduced that GDNF is able to seal 
tightly the paracellular pathway in addition to its homeostasis role on the CNS. Moreover, it 
appears that factors secreted by brain endothelial cells including leukaemia inhibitory factor 
(LIF) can induce astrocyte differentiation. ADFs also influence the functionality of BBB 
carrier-mediated transport systems (Abbott, 2005). The use of BBB transports will be 
discussed later in this chapter. 
2.3 Pericytes  
Pericytes are an imperative cellular constituent of the BBB, which also play a regulatory role 
in terms of brain angiogenesis and tight junction formation within BCECs. These cells also 
contribute to the microvascular vasodynamic capacity and structural stability. They are 
actively involved in the neuroimmune network operating at the BBB and confer 
macrophage functions. The pericyte and endothelial cell interaction occurs via cytoplasmic 
processes of the pericyte indenting the EC and vice versa. This contact process is called "peg 
and socket"-an interdigitation process (Wakui et al., 1989). Larson et al. (1987) studied 
intercellular relationship in the microvasculature using fluorescent Lucifer yellow CH 
dye/radiolabeled nucleotide and freeze-fracture methodology, and showed that cultured 
pericytes presented gap junctions in freeze-fracture replicas and extensive nucleotide and 
dye transfer. Observing low dye transfer and high nucleotide transfer between bovine brain 
microvessel endothelial cells and pericytes, they proposed a possible junctional contact 
between these cells that promotes their differentiation (Larson et al., 1987).  
Basically, some biomolecules including adhesive glycoprotein and fibronectin have been 
found localized at the BCECs and pericytes junctional sites adjacent to "adhesion plaques" at 
the plasma membrane. The adhesion plagues implied the existence of a mechanical linkage 
between pericytes and ECs, i.e. a linkage that allowed mechanical contraction or relaxation 
of the pericyte to influence vessel diameter. This later process may assist the endothelial 
cells to reduce their size. Pericytes have specific and localized distribution in different 
tissues displaying a granular morphology reflecting lysosomal enrichment. Using an in vivo 
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rat model, it has been reported that blood-brain barrier disruption, e.g. by hyperosmotic 
mannitol with adriamycin, causes an increase of pericyte lysosomes (Kondo et al., 1987). 
Pericytes are rich in plasmalemmal and cytoplasmic vesicles as well as microfilament 
bundles, but interestingly only about 10% of vesicles locate to the surface facing ECs. Most 
importantly pericytes modulate endothelial cells phenotype not only by physical action but 
also via secreting epidermal growth factor (EGF). Indeed, it has already been shown that 
EGF is an effective endothelial cell mitogen that enhances angiogenesis, and is concentrated 
at and during pericytes-ECs cross-talk and interdigitation processes. The expression of Ǆ-
GTP has been shown in the pericyte as well as the brain microvessel endothelial cells. Using 
Ǆ-GTP as the sole marker for the primary isolated brain capillary endothelial cells seems not 
to be right and proper due to possible pericytic contamination. The transforming growth 
factor-beta (TGF-b), produced by pericytes, plays an important role in reducing lymphocyte 
infiltration into the CNS in inflammatory demyelinating diseases. Pericytes can stabilize 
capillary-like structures formed by endothelial cells in coculture with astrocytes. This latter 
process can be driven by TGF-b1, which is one of the TGF-b isoforms (Allt & Lawrenson, 
2001; Ramsauer et al., 2002). 
The cultured pericytes in the endothelial cell conditioned-medium (ECCM) allowed the 
cerebral pericyte aminopeptidase N (pAPN) to be re-expressed, while purified pericytes 
deprived of endothelial cells even in the presence of ACM showed no reexpression. This 
indicates that endothelial cells constitute an essential requirement for the in vitro re-
expression of pAPN, but not astrocytes. Pericytes are involved in amino acid and peptide 
catabolism of the brain. This suggests that pericytes play a key metabolic role aside from 
structural role in relation to the BBB maintenance and homeostasis. In addition, based on the 
reciprocal pericytes-ECs interactions and cross talk, it can be suggested that the two-way 
interdigitations may stimulate not only the BBB endothelial cell activities but also promote 
pericyte functions. Pericytes may have a role in the possible cross-talk between pericytes, 
astrocyte and endothelial cells, a triple intercommunication process that may bring us to 
consider the notion of pericyte positive contribution in the physiopathology of the BBB as 
well as certain diseases such as Alzheimer. For example, ǃ-amyloid peptide 42 can be 
uptaken by the phagocytic pericytes and astrocytes. This process helps to clear the 
exogenous peptide from the brain extracellular space and deliver it to the blood circulation 
system that shows also the contribution of pericytes in the BBB transport functionality (Allt 
& Lawrenson, 2001; Balabanov & Dore-Duffy, 1998; Pluta et al., 2000).  
3. Bioelectrical properties and permeability  
Due to the association of the TEER with permeability, TEER values commonly are exploited 
to describe the permeability of the BBB. The [14C] sucrose permeability is used to assess the 
restrictiveness of BBB in relation to in vivo (1.2  10-7 cm.sec-1). In vivo TEER values vary in 
the epithelial and endothelial cells. For instance human placental endothelium shows TEER 
22–52 Ω.cm2 that permits rapid paracellular exchange of nutrients and waste between the 
mother and fetus (Jinga et al. 2000), whereas urinary bladder epithelium has a very high 
TEER of 6000–30000 Ω.cm2, necessary for preserving urine composition (Powell 1981). The 
BBB possesses TEER vales of ~2000 Ω.cm2, which helps to maintain brain homeostasis 
(Engelhardt, 2006).  
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Efforts to generate an in vitro BBB model, in fact, have been based upon measurement of the 
TEER, assessment of the sucrose permeability and expression of the specific enzymes and 
markers of the BBB. The higher TEER and the lower sucrose permeability confer the better 
characteristics. To achieve this aim different techniques have been recruited, e.g. utilizing of 
the hydrocortisone and serum free medium in order to increase the TEER (up to 1000 cm2) 
by stimulating the formation of barrier properties (Hoheisel et al. 1998).  
4. Modulation of BBB permeability 
4.1 Extracellular matrix  
The influence of extracellular matrix on the BBB properties has been investigated by several 
researchers using cell lines and primary isolated BCECs. Shivers et al. (1988) showed that the 
local control of tight junction biogenesis in brain capillary endothelial cells depends on 
astrocyte-produced factors and extracellular matrix. The ECs in general do not express their 
final destination-specific differentiated features until those features are induced by local 
environment-produced conditions including extracellular matrix. Using primary cultures of 
PBCECs, Tilling et al. (1998) examined the effect of collagen IV, fibronectin, laminin and a 
secreted acidic protein and rich in cysteine alone or one-to-one mixtures of them. They 
showed that these proteins are involved in tight junction formation between cerebral 
capillary endothelial cells by presenting increased TEER (Robert & Robert, 1998; Tilling et 
al., 1998). 
4.2 The role of cyclic AMP (cAMP)  
The effect of cAMP on BBB function has been studied by several researchers. Using 
combination of astrocyte conditioned-medium and cAMP elevators, Rubin et al (1991) 
reported a cell culture in vitro BBB model that generated high resistance tight junctions and 
exhibited low rates of paracellular permeability. Hurst et al (1996) showed that a coculture 
BBB model of the immortalized human umbilical vein endothelial cells ECV304 ( reassigned 
later as T24 bladder epithelial carcinoma cell) with rat C6 glioma cells can generate a BBB 
model with high TEER (400-600 .cm2). They demonstrated bioelectrical alterations by 
vasoactive agonists and cAMP elevators (i.e. decreased TEER by histamine, bradykinin, and 
serotonin and increased TEER by cAMP, such as forskolin elevators). The researchers also 
showed formation of inositol triphosphates (IPs) that can induce the release of calcium ions 
from cellular storage sites and a subsequent rise in intracellular calcium which can activate 
diacylglycerol (DAG) and accordingly the PKC that could increase the permeability of the 
endothelial cells (Hurst & Clark, 1998). Investigation on the effects of elevated intracellular 
cAMP and astrocyte derived factors on the F-actin cytoskeleton and paracellular 
permeability of RBE4 cell monolayers have revealed that the cAMP effects on the TEER 
appear likely to be independent of new gene transcription (Rist et al., 1997).  
The protein GDNF can activate the barrier functions of the BCECs in the presence of cAMP. 
It has been reported that GDNF not only can promote the barrier restrictiveness but also 
support the survival of neurons in the presence of cAMP. The role of other factors on brain 
ECs signaling and the BBB formation is uncertain (Igarashi et al., 1999). However, some 
other factors such as vascular endothelial growth factor (VEGF) appear to increase the 
permeability of BCECs because of loss of occludin and ZO-1 from the endothelial cell 
www.intechopen.com
 Novel Therapeutic Concepts in Targeting Glioma 120 
junctions (Wang et al., 2001), while cAMP acts against such phenomenon. All of these 
processes, somehow, play a role in modulating the full BBB characteristics. By means of an 
unpassaged primary culture of rat BCECs, it has been shown that certain cell-surface 
receptors may fulfill a role in BBB regulation. For example, brain endothelial regulation was 
shown by P2Y2 receptors coupled to phospholipase C, Ca2+ and MAPK; and by P2Y1-like 
(2MeSATP-sensitive) receptors that are linked to Ca2+ mobilization. It should be stated that 
differential MAPK coupling of these receptors appear to exert fundamentally distinct 
influences over brain endothelial function in terms of cAMP modulation (Albert et al., 1997). 
4.3 Inflammatory mediators 
Basically, the brain endothelium forming the BBB can be modulated by a range of 
inflammatory mediators. Given that the main routes for penetration of polar solutes across 
the BBB include the paracellular tight junctional pathway and vesicular machineries, 
inflammatory mediators appear to influence both pathways, while such impacts can also be 
seen in other closely associated cells such as pericytes, astrocytes, smooth muscle, microglia, 
mast cells, and neurons. Various inflammatory agents are able to increase both endothelial 
permeability and vessel diameter, and these together can result in significant leakiness of 
BBB and accordingly cerebral edema. Of these agents, the bradykinin (Bk) is able to 
increases the permeability of BBB by acting on B2 receptors, perhaps via elevation of Ca2+, 
activation of phospholipase A2, release of arachidonic acid, and production of free radicals. 
Serotonin (5HT) can also increase the permeability of BBB through a calcium-dependent 
mechanism. Histamine as nervous system neurotransmitters possesses capability of 
consistent blood-brain barrier opening mediated by H2 receptors and elevation of Ca2+, but 
the H1 receptor coupled to an elevation of cAMP can decrease the permeability of BBB. 
Elevation of arachidonic acid may also cause gross opening of the BBB to large molecules 
such as peptides/proteins. There exist a number of studies showing purposed recruitment 
of such mechanisms for deliberate opening of the BBB for drug delivery to the brain; readers 
are directed to see (Abbott, 2000).  
5. BBB enzymes and other differentiation markers 
Several markers are most commonly exploited and include Ǆ-GTP and alkalin phosphatase 
(ALP) enzymes expression, or antigenic endothelial cell markers such as: Factor VIII , von 
Willebrand Factor (vWF). Additionally the uptake of acetylated low density lipoprotein 
(LDL) i.e. dioctadecyl-indocarbocyanine (Di-I) labeled acetylated LDL (Di-I-Ac-LDL)  and 
the binding of lectin, i.e. biotinylated lectins (BL) Ultex europaeus I (UE I) and Bandeiraea 
simplicifolia isolation B4 ( BSA IB4) have been exploited. Further, a high glucose transporter 
(GLUT-1) density has been shown as a marker of brain microvascular endothelia. The -
GTP, ALP and membrane peptidases (aminopeptidase N, peptidyle dipeptidase and 
dipeptidyl peptidase IV) have been used as marker for the BBB. The -GTP is of special 
importance due to its high expression in the BCECs, therefore it is used as a marker for ECs 
of the BBB. By contrast, this marker is absent from brain ECs of paraventricular nucleus, 
where the BBB characteristics and properties are lacking. The induction of -GTP by 
astrocyte has been reported, even though the high expression of this enzyme in the pericytes 
makes it a non-specific marker of the BBB. The ALP is highly expressed in the BCECs and 
used as a marker. Like Ǆ-GTP, its expression can be modulated by astrocytes. The 
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metabolism of neuropeptides is mediated by membrane peptidases at the BBB. Three 
members of the membrane peptidases (dipeptidyl peptidase A; aminopeptidase N; 
dipeptidyl peptidase IV) have been found in the BCECs, but many more vessels are positive 
for them, in particular more positive for dipeptidyl peptidase A than other two. The 
expression of the BBB enzymes depends on the different parameters such as direct cell-to-
cell communications or cell-derived factors. Enzymatic activities of the -GTP and ALP are 
taken as indicators for the expression of the BBB phenotype; reader is directed to see (Allt & 
Lawrenson, 2000; Allt & Lawrenson, 2001; Orte et al., 1999).  
6. Transportation of exogenous/endogenous compounds across BBB  
The capability of a particular substance to cross the BBB and enter the CNS is dependent 
upon a number of parameters, including physicochemical properties such as molecular 
weight (MW), lipophilicity, pKa, hydrogen bonding as well as biological factors. The BBB 
transportation, nevertheless, may generally be classified into different categories, including: 
1) passive diffusion that depends on physicochemical properties and mainly on the 
lipophilicity of the molecule, 2) facilitated transport via carrier-mediated transporters 
(Glut1, LAT1), 3) paracellular pathway (small hydrophilic componds), 4) receptor-mediated 
endocytosis/transcytosis, and 4) Liquid-phase (adsorptive) endocytosis/transcytosis. Fig. 3 
represents schematic illustration of BBB transport systems. 
Brain drug delivery and targeting requires overcoming the limited access of drugs to the 
brain. Different methods have been developed to achieve BBB penetration, including: 
opening of BBB TJs by means of osmotic or biologically active agents (such as bradykinin 
and histamine); exploiting of various specific transport mechanisms. The last methodology 
includes: conjugation of a drug with a targeting protein, or to a monoclonal antibody that 
gains access to the brain by receptor-mediated transcytosis, or to a small peptide-vectors to 
enhance brain uptake of several therapeutic drugs. Further the use of drug delivery devices 
such as liposomes has also been reported. As shown in Fig. 4, the BBB carrier-mediated 
transporters comprise two different classes, including the efflux and the influx pump 
transport systems.  
6.1 Efflux transporters 
The BBB represents a major hindrance to the entry of many therapeutic drugs into the brain 
and efflux pumps are part of this protection. P-glycoprotein (P-gp; MDR1/ABCB1)  is an 
ATP-binding cassette (ABC) drug transport protein that is predominantly found in the 
apical membranes of a number of epithelial cell types in the body as well as the brain 
microvessel endothelial cells. The putative transmembrane structural organization of human 
MDR1 P-gp is primarily found in the cell plasma membrane as 12 transmembrane segments 
that are thought to fold together and form a three-dimensional barrier like structure in the 
cell plasma membrane. The latter polypeptide chain consists of two similar halves. Each half 
contains of six putative transmembrane segments and intracellular ATP-binding site. The 
hydrolysis of ATP provides the energy for active drug export. Schinkel et al (1995) showed 
that mouse MDR1a and the human MDR1 P-glycoprotein actively transport ivermectin, 
dexamethasone, digoxin, and cyclosporin A and, to a lesser extent, morphine across a 
polarized kidney epithelial cell layer in vitro. The investigator reported that injection of the 
radiolabeled substrates of P-gp in MDR1a knockout and wild-type mice resulted in 20- to 
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50-fold higher levels of radioactivity in the MDR1a knockout mice brain for digoxin and 
cyclosporin A (Schinkel et al., 1995b). These researchers generated mice with a genetic 
disruption of the drug-transporting MDR1a P-gp and showed that the P-gp knockout mice 
were overall healthy but they accumulated much higher levels of substrate drugs in the 
brain with markedly slower elimination. For the drugs (e.g., anticancer agents) that are P-gp 
substrates, this can lead to dramatically increased toxicity (Schinkel et al., 1995a). Thus, 
drugs inhibiting the MDR1 P-gp activity should be co-administered during chemotherapy of 
the brain tumors. The authors concluded that P-gp is the major determinant for the 
pharmacology of several medically important drugs apart from anti-cancer agents, 
especially in the BBB. 
 
Fig. 3. Schematic illustration of transportation systems for shuttling of endogenous and/or 
exogenous substrates at the BBB. 1) Lipid-soluble small substrates (<500 Da) are able to 
diffuse across the membrane – they may be effluxed back into the blood circulation through 
efflux transporters (e.g., P-gp, MRP4). 2) Carrier-mediated transport machineries (e.g., 
Glut1, LAT1) are responsible for transport of small endogenous molecules (e.g., amino acids, 
nucleosides, and glucose). 3) Some small hydrophilic molecules can be transported via 
paracellular route. 4) Larger molecules (e.g., insulin, transferrin) are transported through 
receptor-mediated endpcytosis/transcytosis using vesicular trafficking towards the brain 
parenchyma. 5) Some large proteins (e.g., albumin) are transported across the BBB by 
adsorptive-mediated endocytosis/transcytosis. Of the carrier-mediated transporters, 
glucose transporters (Gluts) are responsible for traverse of glucose from blood to brain and 
btween different cells within the brain parenchyma. Adherens junctions provide a path for 
cell-to-cell intercommunication within endothelial cells of the BBB, adapted with permission 
(Omidi & Barar, 2012).  
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Multidrug-resistance associated protein (MRP) (Zhang et al. 2000) actively transports a 
broad range of anionic compounds out of the cell in the BBB and is known as another 
member of the ABC superfamily of transport proteins. It has approximately 15% amino acid 
sequence homology to P-gp, and the characteristics ATP binding sites that allow for the 
active transport of a diverse array of compounds out of the cell. In contrast to P-gp, MRP 
transports organic anions. Zhang et al (2000) reported that the MRP1, MRP4, MRP5, and 
MRP6 were consistently expressed in both the capillary-enriched fraction of the brain 
homogenate and the BBMEC monolayers. The expression of MRP2 has also been shown in 
the isolated primary porcine microvessel endothelial cells (Fricker et al. 2002). The presence 
of several different MRP homologues at the BBB highlights the MRP role in controlling the 
permeability of the BBB to organic anions. In the brain, MRP4 was shown to be expressed on 
the luminal membrane of BCECs as well as the basolateral membrane of the choroid plexus. 
The chemotherapeutic drug topotecan was shown to be accumulated in the brain and the 
CSF in an MRP4 knockout mouse model. This clearly highlights the important role that 
MRP4 plays in determining the CNS distribution of this drug (Leggas et al., 2004). It is likely 
that multiple efflux drug transporters including MRP4 govern the brain penetration and 
activity of this anticancer agent. Readers are directed to see (Tsuji, 2005; Urquhart & Kim, 
2009). 
It should be stated that most of anticancer agents are substrate to ABC transporters. Of these, 
the MDR1/ABCB1 can pump out a wide range of compounds (e.g., Acebutolol, Actinomycin 
D, Amprenavir, Azidopine, Betamethasone, Calcein-AM, Cepharanthin, Cerivastatin, 
Chloroquine, Cimetidine, Clarithromycin, Colchicine, Cortisol, Cyclosporin A, Daunorubicin, 
Dexamethasone, Digitoxin, Digoxin, Dipyridamole, Docetaxel, Domperidone, Doxorubicin, 
Eletriptan, Emetine, Epinastine, Erythromycin, Estradiol-17b-D-glucuronide, Estrone, Ethynyl 
estradiol, Etoposide, Fexofenadine, Grepafloxacin, Imatinib, Indinavir, Irinotecan, Ivermectin, 
Lansoprazole, Levofloxacin, Loperamide, Losartan, Lovastatin, Methylprednisolone, 
Mitoxantrone, Morphine, Neostigmine, Omeprazole, Pantoprazole, Prazosin, Prednisolone, 
Puromycin, Quinidine2, Ramosetron, Ranitidine, Reserpine, Ritonavir, Saquinavir, 
Somatostain, Sparfloxacin, Talinolol, Taxol, Terfenadine, Trimethoprim, Vecuronium, 
Verapamil, Vinblastine, Vincristine), while the MRP4/ABCC4 is able to efflux a narrower 
spectrum (e.g., cAMP, cGMP, Dehydroepiandrosterone-3-sulfate, Estradiol-17b-D-
glucuronide, Folate, Methotrexate, Prostaglandin E1, Prostaglandin E2). The breast cancer 
resistance protein (BCRP/ABCG2) have been reported to be expressed as active efflux drug 
transporters at the BBB that can display efflux functionality similar to that of P-gp for a wide 
range of componds (e.g., Azidodeoxythymidine, Bisantrene, Cerivastatin, Doxorubicin, 
Daunorubicin, Dehydroepiandrosterone-3-sulfate, Etoposide, Estrone-3-sulfate, Estradiol-17b-
D-glucuronide, Folate, Flavopiridol, Imatinib mesylate, Mitoxantrone, Methotrexate, Prazosin, 
Pantoprazole, Pravastatin, Rhodamine 123, Topotecan), for more details readers are directed to 
see (Ohtsuki & Terasaki, 2007). 
Many of these chemicals are important anticancer agents (e.g., Doxorubicin, Vinblastine, 
Vincristine, Methotrexate, Docetaxel, Etoposide, Idarubicin, and Taxol), thus it is vital to 
inhibit these efflux machineries to reach suitable concentration in brain during brain tumors 
chemotherapy. Various compounds were reported as inhibitors for these efflux 
transportsers such as colchicine, phenothiazines and quinacrine.  
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6.2 Influx transporters 
BBB influx transporters can be divided into different groups as follows:  
1. the energy transport systems for transport of glucose and mannose (Glut1); lactate, 
short-chain fatty acids, biotin, salicylic acid and valproic acid (MCT) and creatine 
(CRT), 
2. the amino acid transport systems such as small (LAT2/4F2hc) and large (LAT1/4F2hc) 
neutral amino acid transporter systems for transport of neutral amino acids and L-dopa; 
acidic amino acid transporter for aspartate and glutamate (ASCT2); basic amino acid 
transporter (BAAT) for arginine and lysine; the -amino acid transporter for -alanine 
and taurine (TAUT); System A (ATA2) for small neutral amino acids; System 
ASC/system B0+, 
3. the organic anion transport system such as OATP2 for digoxin and organic anions,  
4. the nucleoside transport systems such as ENT2 and CNT2,  
5. the peptide transport systems such as oligopeptide transporters (PepT1, PepT2), 
polypeptid transport systems such as OAT3 for PAH, HVA, indoxyl sulfate; OATP14 
for thyroid hormones, 
6. the neurotransmitter transport systems such as GAT2/BGT1, SERT and NET 
respectively for transport of -aminobutyric acid, serotonin and norepinephrine, and  
7. the choline transport system for choline and thiamine (Ohtsuki & Terasaki, 2007). 
Given that the main properties of the BBB that differ the brain capillary endothelia from 
other blood microvessel because of the presence of restrictive high-resistance tight junctions 
between blood and brain parenchyma, the BBB forming BCECs almost completely prevents 
the uptake of potential CNS drugs via the paracellular pathway. Thus compounds passing 
the BBB almost exclusively have to exploit the transcellular pathway, but this is not always 
the case since there are increasing evidences that a broad variety of transport machineries 
are involved, including both carrier-mediated transport and receptor-mediated transcytosis 
for transporting compounds into the brain (the so called active influx) and multidrug 
transport pumps for actively effluxing unwanted chemicals out of brain (the so called active 
efflux). In the case of transport into the brain, numerous systems have been discovered, 
including transport proteins for amino acids, monocarboxylic acids, organic cations, 
hexoses, nucleotides and peptides. Several of these proteins have successfully been used in 
prodrug strategies to enable or at least enhance brain uptake of neurotherapeutic agents. 
Classic examples are l-dopa and progabide. Of these influx transport machineries, both 
pyrimidine and purine nucleoside analogs are currently used clinically as anti-metabolite 
drugs. Cytarabine, an analog of deoxycytidine (1--d-arabinofuranosylcytosine, araC, 
Cytosar-Us), is used as combination chemotherapy in the treatment of chronic myelogenous, 
leukemia, multiple myeloma, Hodgkin’s lymphoma and non-Hodgkin’s lymphomas; 
Gemcitabine (dFdC, 2',2'-di.uorodeoxycytidine, Gemzars), a broad spectrum agent, which is 
used for treatment of a variety of cancers including pancreatic and bladder cancers. 
Capecitabine (5'-deoxy-5-N-[(pentoxy) carbonyl]-cytidine, Xelodas) is used, as a prodrug, in 
treatment of metastatic colorectal cancer. Two purine nucleoside anti-metabolite drugs, 
Fludarabine (9--d-arabinofuranosyl-2-.uoroadenine), and Cladribine (2-chloro-2'-
deoxyadenosine, CdA, Leustatins) are used for treatment of low-grade lymphomas and 
chronic lymphocytic leukemia (Omidi & Gumbleton, 2005).  
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Fig. 4. Carrier-mediated transporters of the BBB (efflux and the influx transport systems) at 
luminal and basolateral membranes, adapted with permission from (Omidi & Barar, 2012). 
Astrocytes, neurons and microglial cells are intercommunication with brain capillary 
endotheilal cells. P-gp: P-glycoprotein. MRP1: multidrug resistance associated protein 1. 
MRP4: multidrug resistance associated protein 4. MRP5: multidrug resistance associated 
protein 5. BCRP: breast cancer resistance protein. Glut1: glucose transporter 1.  
MCT1: monocarboxylate transporter 1. LAT1: large neutral amino acids transporter 1. 
ASCT2: neutral amino acid transporter 2. EAAT: excitatory amino acid transporters.  
CNT2: centrative nucleoside transport 2. ENT: equilibrative nucleoside transport 2.  
SERT: serotonin transporter. NET: norepinephrine transporter. CRT: creatine transporter. 
TAUT: taurine transporter. OATP2: organic anion-transporting polypeptide. OAT3: organic 
anion transporter 3. OATP1A2: organic anion-transporting polypeptide. OAT2: organic 
anion transporter 2. 
6.3 Endocytosis, transcytosis and exocytosis  
Cell membranous vesicular machinery domains comprise numerous components including 
lipid rafts, caveolae and clathrin-coated pits. All of them appear to participate in endocytosis 
and probably transcytosis of macromolecules.  
Caveolae are flask-shaped invaginations of the plasma membrane coated by a 22 kDa 
structural protein caveolin. Initially detected in endothelial cells, caveolae tend to mediate 
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the selective uptake of molecules as small as folate to full size proteins such as albumin and 
lipoproteins. These micro-domains are highly enriched in glycosphingolipids, cholesterol, 
sphingomyelin, and lipid-anchored membrane proteins. Caveolae have been implicated in a 
wide range of cellular functions including transcytosis, receptor-mediated uptake, 
stabilization of lipid rafts and compartmentalization of a number of signaling events at the 
cell surface. Several studies have also shown that caveolae-mediated uptake of materials is 
not limited to macromolecules; in certain cell-types, viruses (e.g. simian virus 40) and even 
entire bacteria (e.g. specific strains of E. Coli) are engulfed and transferred to intracellular 
compartments in a caveolae-dependent fashion. Clathrin-mediated endocytosis is the most 
widely studied vesicular membrane internalizing system, and participation of clathrin-
coated vesicles has also been investigated in terms of receptor-mediated transport in the 
BBB. Clathrin forms a non-covalently bound triskelion structure composed of three heavy 
chains (192 kDa each) and three light chains (Omidi & Gumbleton, 2005; Smith & 
Gumbleton, 2006). Fig. 5 represents schematic illustration of the clathrin coated vesicles 
(CCV) and its main protein “triskelion”.  
 
 
Fig. 5. TEM micrograph (A) and schematic representation of molecules involved in assembly 
of the clathrin coated pit (B) and its main protein triskelion (C). TEM: transmission electron 
microscopy; CCV: clathrin coated vesicle (Omidi & Barar, 2012). 
7. BBB cell culture models  
A simple, applicable, and robust in vitro cell based BBB model can provide a useful tool for 
screening of permeability to central nervous system-acting drugs. Thus, in the 1970s, 
techniques for isolation of brain microvessels were introduced using mechanical or 
enzymatic homogenization. In the late 1970’s, BCECs were plated in tissue culture and this 
led to the early in vitro BBB model establishment (DeBault et al., 1979). The primary BCECs 
cultures are very well-characterized systems used as in vitro models; nevertheless they have 
the disadvantage of being very laborious and variable and must be repeated often to 
provide an adequate stock of cells. Therefore various immortalized endothelial cell lines 
have been developed and examined such as CR3, EC219, RBE4  b.End3, ECV304, and even 
epithelial cell line MDCK.  
www.intechopen.com
 Blood-Brain Barrier and Effectiveness of Therapy Against Brain Tumors 127 
Basically, an appropriate cell culture model confers a useful platform for not only 
transcellular and paracellular drug diffusional processes, but also metabolism and active 
transport processes. Such model can be used for investigating the nondefined interactions 
between a drug and cellular material that may impact upon a membrane's overall 
permeability profile. Thus, ideally the in vitro BBB cell model should represent a restrictive 
paracellular barrier functionality, physiologically realistic cell architecture and functional 
expression of key transporter mechanisms. Such model should also confer ease of culture to 
meet the technical and time constraints of a screening program. Based upon these facts, 
immortalized cell based BBB models often fail to meet all these essentialities. 
Despite many benefits of immortalized cell based BBB models, the lack of restrictive barrier 
function has limited their use for permeability screenings and therefore the primary BCECs 
have been isolated to be used as a cell culture BBB in vitro model. The main advantage from 
pharmaceutical perspective is that these primary models, practically the bovine and porcine 
models, possess a restrictive paracellular pathway. Nevertheless, BCECs grown in tissue 
cultures probably lack many of the characteristics of the BBB in vivo. In an attempt to 
improve such models, endothelial/astrocyte and endothelial/pericyte cocultures have been 
examined, even attempts to generate a 3 dimensionals (3D) model have been made. For 
instance aortic cells cocultured with astrocytes (C6 cells) in the presence of flow within 
hollow fiber tube develop a selective barrier with an estimated electrical resistance of 2,900 
.cm2 (Stanness et al., 1996). The same group later reported that the previously introduced 
3D dynamic in vitro BBB model can be successfully used for the coculture of differentiated 
serotonergic neurons in the presence of a BBB (Stanness et al., 1999). A number of less-
complicated in vitro coculture BBB models have also been established and developed. To 
produce continuous BBB in vitro models, several academic groups have reported the 
generation of immortalized brain microvessel endothelial cell lines. An immortalized 
human brain capillary endothelial BB19 cell line was transformed with the E6E7 genes of 
human papilloma virus and retained their endothelial nature. It was used to study the 
cytoadherence of Plasmodium falciparum-infected erythrocytes (Prudhomme et al., 1996). 
Human cerebral microvascular endothelial cells SV- HCEC, transfected with the plasmid 
pSV3-neo coding for the SV40 large T antigen, was utilized to serve as a human BBB in vitro 
model showing the expression of factor VIII-related antigen, the uptake of acetylated low- 
density lipoprotein, the binding of fluorescently labeled lectins, the expression of transferrin 
receptor, and high activities of the ALP and Ǆ-GTP (Muruganandam et al., 1997). 
Immortalized brain capillary endothelial cell lines (TM-BBB1-5) were established from 3 
transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene 
displaying the expression of Glut-1 and P-gp. The TR-BBB cell line has also been established 
using same approach from a transgenic rat (Hosoya et al., 2000). An immortalized rat brain 
endothelial cell line, RBE4, was immortalized by transfection with a plasmid containing the 
E1A adenovirus gene (Roux et al., 1994). The RBE4 cell line appears to be most commonly 
used cell line to be exploited for investigation of different features of BBB, e.g. the transport 
of insulin, the expression of P-gp, the uptake of L-dopa and the expression of transferrin 
receptor (Balbuena et al., 2011; Hulsermann et al., 2009; Yu et al., 2007). The MBEC4 cells, 
established from BALB/c mouse cerebral microvessel endothelial cells, were used to 
investigate the high-affinity efflux transport system for glutathione conjugates (Homma et 
al., 1999). The CR3 cells, established by genomic introduction of the immortalizing SV40 
large T gene under the control of the human vimentin promoter, displayed endothelial 
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morphological and biochemical characteristics for up to 30 passages. The b.End3 cells was 
used to study the uptake and efflux of transferrin (Tf) and Fe showing the expression of Tf 
receptor and suggesting a receptor-mediated endocytosis for the uptake (Lechardeur et al., 
1995; Lechardeur & Scherman, 1995). Given that the immortalized continuous cell lines tend 
not to generate a restrictive barrier property, isolated primary BCECs have been used from a 
variety of sources including human, bovine, porcine, monkey, rat, canine, and murine. For 
more details, readers are directed to see following citations (Gumbleton & Audus, 2001; 
Lacombe et al., 2011; Ribeiro et al., 2010).  
8. BBB permeation and in-slico prediction models 
Undoubtedly, the BBB is designed to protect the brain from entering of toxic compounds. As 
outlined above, the main underlying concept seems to be to force the compounds to take the 
transcellular route, where nutrients are actively transported into the brain and possibly toxic 
compounds are expelled via active efflux pumps. Thus, BBB permeation is a multifactorial, 
complex issue which requires advanced computational methods for proper modeling. 
Computational models, in general, exploit two different approaches. The passive diffusion-
controlled permeability is dependent upon the inherent physicochemical characteristics 
(e.g., logP, solubility and surface area) of the compounds, and basically molecular descriptor 
based methods are used to generate predictive models. The ligand-receptor (i.e., 
influx/efflux transporters, or receptor mediated endocytosis) active/facilitated transport 
can be considered for carrier/receptor mediated trafficking. Given these, predictive in-silico 
models suitable for both the lead identification and the lead optimization processes should 
include both categories. The most commonly used type of data appear to be the logBB 
values that are described as the ratio of the steady-state concentration of a designated 
compound in the brain to that of the blood which can describe by Equation (1). 
 LogBB=Log([CBrain]/[CBlood])  (1) 
The most commonly used in vitro model for BCECs culture is based on Transwell™ system, 
which consists of a porous membrane support submerged in culture media. This system is 
normally characterized by two direction diffusion, i.e. apical to basal (A to B) or basal to 
apical (B to A). Given existence of large number of drug-like compounds (e.g., 
ChemNavigator), a very small number of molecules have been drawn to carefully monitor 
the main permeation driving/limiting force (i.e. passive diffusion, active influx or active 
efflux), however the data available mostly represent both passive and active transport 
phenomena. For detailed information, reader is directed to see (Wolburg, 2006). 
8.1 Passive diffusion  
Having assumed that the rate of drug release from the formulation is not rate-limiting, the 
absorption of drug molecules across BBB depend upon: 1) the rate of drug dosing which 
takes into account the administered dose (mass) and the dosing interval (τ ; time), 2) the 
interactions of drug molecules with circulating biomolecules in blood (protein binding), 3) 
drug biostability and clearance, 4) the apparent absorption rate constant for the drug (Ka; 
time-1). Clearly the stability of drug during the absorption process and importantly the 
intrinsic permeability of the BBB to the drug are critical factors in determining logBB.  
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Passive diffusion involves the movement of drug molecules down a concentration or 
electrochemical gradient without the expenditure of energy. Firstly, if we consider only the 
transport of drug molecules across BBB via passive diffusional processes then the overall 
flux (J) of a drug in one dimension (i.e. the net mass of drug that diffuses through a unit area 
per unit time) can be described by Equation (2). 
   p
t
dCJ D K A
dx
        (2) 
Where J is the flux of drug; D is the diffusion coefficient of drug across the cellular barrier; 
Kp is a global partition coefficient (cell membrane/aqueous fluid); A is the surface area of 
the barrier available for absorption; x is the thickness of the absorption barrier, and (dC/dx)t 
is the concentration gradient of drug across the absorption barrier. The negative sign in 
Equation (2) indicates that diffusion proceeds from high to low concentration and hence the 
flux is a positive quantity. In fact, the greater this concentration gradient, the greater the rate 
of diffusion of a drug across the cell membrane.  
The apparent permeability coefficient () of an epithelial/endothelial barrier to a given 
drug approximate D.Kp. The processes of drug partitioning with the biomembrane 
(including partitioning between extracellular fluid and plasma membrane, partitioning 
between plasma membrane and cell cytosol, and other organelle interactions etc.) and of 
drug diffusion across the biomembranes (including a range of organelle and 
macromolecule interactions that will influence the diffusion process) are largely 
dependent upon the molecular properties of the drug, i.e. molecular size/shape, ionic 
properties (hydrogen bonding potential, pKa), and hydrophobic properties. Basically, 
such molecular properties will determine if passive diffusional transport across an 
epithelial/endothelial barrier involves either a predominantly paracellular (between cells) 
pathway negotiating a tortuous intercellular route via the aqueous channels formed by 
the anastomosing tight junctional fibrils between adjacent cells, or predominantly (but not 
exclusively) transcellular (across the cell) pathway requiring partitioning of drug into the 
plasma membrane bilayer. In fact, it should be stated that if a drug’s molecular properties 
afford partitioning into biomembranes (i.e. nonionized form of the drug predominates 
and is of a sufficient hydrophobic nature) then the membrane surface area available for 
transcellular diffusion will be considerably greater, by many orders of magnitude, than 
the surface area available for diffusion via the paracellular route. As a corollary, the 
transcellular diffusion can potentially result in a higher permeability and a higher rate 
and extent of absorption. For detailed information, reader is directed to see (Omidi & 
Gumbleton, 2005; Wolburg, 2006) 
8.2 Macromolecular permeation  
With respect to in-silico methods, the passive diffusion seems to be well described by 
physicochemical parameters of the respective solutes (e.g., lipohilicity, H-bond 
acceptor/donor features, molecular weight, polar surface area, number of rotatable bonds). 
These descriptors can be simply calculated and are thus a versatile tool for high-throughput 
in-silico screening of large compound databases. Basically, small hydrophilic molecules 
exploit the paracellular pathway to diffuse into organs (Fig. 3).  
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The impact of the molecule’s steric, ionic and hydrophobic properties upon passive 
membrane transport and epithelial/endothelial permeability are equally applicable for 
peptides, proteins and nucleic acids, as they are for traditional low molecular weight drugs. 
Nevertheless, their permeation across biological barriers will be limited by the presence of a 
significant number of hydrogen bond acceptor and donor groups, i.e. requiring considerable 
desolvation energy for the molecule to leave the aqueous environment and partition into a 
biological membrane. The diffusion of macromolecules (peptides, proteins and nucleic 
acids) across biological membranes appears to be through endocytosis/transcytosis route or 
in some cases via the paracellular pathway (Fig. 3). For example, to pursue the binding, 
uptake and transcytosis of 60 nm porous nanoparticles (NPs) differing in their surface 
charge and inner composition, Jallouli et al studied their trafficking at the BBB. Having used 
maltodextrins with/without a cationic ligand, they showed that the cationic NPs were 
accumulated mainly around the paracellular area, while neutral NPs were mainly on the cell 
surface and the dipalmitoyl phosphatidyl glycerol (DPPG) NPs were at both paracellular 
areas and on the surface of the cells. It was shown that filipin can increase the binding and 
uptake (sterols may entail in their efflux), while decrease the transcytosis of neutral NPs. 
They concluded that the neutral NPs, like LDL, exploit the caveolae pathway and suggested 
the neutral and cationic 60 nm porous NPs as potential candidates for drug delivery to the 
brain (Jallouli et al., 2007). It is believed that Tf receptor, as a molecular part of vesicular 
trafficking, can facilitate brain delivery of NPs in vivo. To explore the attributed mechanism 
of this process, Chang et al evaluated the endocytosis of poly(lactic-co-glycolic acid) (PLGA) 
NPs coated with transferrin using an in vitro coculture of BCECs and astrocytes. Using 
solvent diffusion method, they prepared PLGA NPs by means of DiI as a fluorescent marker 
and coated with Tween 20, BSA and Tf. Depending upon DiI incorporation and surface 
coating, the size of NPs varied from 63 to 90 nm. In comparison with BSA NPs, the Tf-NPs 
were found to be highly adsorbed BCECs through an energy-dependent process. Having 
used specific inhibition, these researchers showed that the Tf-NPs can interact with BCECs 
in a specific manner and enter the cells via the caveolae endocytic pathway (Chang et al., 
2009). Having used a cross-reacting material 197 (CRM197) which is a non-toxic mutant of 
diphtheria toxin, Wang et al reported that the apical-to-basal transcytosis of CRM197 can 
involve the caveolae-mediated pathway in the hCMEC/D3 endothelial cells as the caveolin-
1 mRNA and protein expression levels were significantly increased by CRM197. These 
researchers speculated that the upregulation of caveolin-1 may be mediated via a PI3K/Akt 
dependent pathway and reduction of the phospho-FOXO1A (forkhead box O) transcription 
factor. Based upon such findings, it was proposed that carrier protein CRM197-mediated 
delivery across the BBB is involved in the induction of FOXO1A transcriptional activity and 
upregulation of caveolin-1 expression (Wang et al., 2010). In fact, the BCECs exploit a 
variety of endocytic pathways (i.e., clathrin-mediated endocytosis, caveolar endocytosis, 
and macropinocytosis) for the internalization of exogenous materials. It is deemed that the 
properties of drug delivery vehicles can direct the intracellular processing in brain 
endothelial cells. Using fixed-size NPs, it has been shown that surface modifications of 
nanoparticles (e.g., charge and protein ligands) can affect their mode of internalization by 
BCECs and thereby the subcellular fate (Georgieva et al., 2011). 
It should be also evoked that the diffusion coefficient of a drug is inversely proportional to 
its molecular weight, and while for traditional low molecular weight drugs (100-500 Da) the 
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diffusion coefficient varies little between drugs. Further, the epithelial permeability of 
biotechnology products, like that of traditional low molecular drugs, are subjected to the 
extent of degradation occurring within the barrier itself, in which the role of proteases and 
nucleases will be important for biotechnology drugs, readers are directed to see (Wolburg, 
2006).  
9. Targeting brain tumours  
The integrity of the BBB in metastatic cancerous tumors appears to be different from the 
normal ones. In addition to the various morphological alterations of BBB in metastatic 
cancerous tumors (e.g., compromised tight junction structure and increases in the 
perivascular space, fenestrated BCECs, increased number and activity of pinocytic vacuole), 
the expression of transporters has also been reported to be altered in the microvasculature of 
the brain tumors. This implies that the BBB is less intact in primary and metastatic brain 
tumors compared with the normal brain vasculature, and accordingly the pharmacotherapy 
of brain tumors demands specific strategies. So far, to enhance the amount of therapeutic 
agent to a brain tumor, a number of strategies have been exploited including: 1) increasing 
drug plasma concentration (e.g., intraarterial infusion), 2) physicochemical modification to 
increase drug permeability, 3) design of inactive drug precursors (the so-called prodrugs) 
that could more easily cross the blood–brain barrier before conversion to a drug with active 
formulation, and 4) osmotic disruption of the blood–brain barrier using osmotic-disruptive 
agents such as mannitol (Provenzale et al., 2005). Of these methodologies, liposomal 
formulations seem to be promising since they can passively target tumors in which there is 
disorganized vasculature. This appears to be also related to higher permeability than to 
disorganization per se; nonetheless specific features (e.g., vesicle size, chemical affinity, and 
thermal/pH sensitiveness) may affect the targeting potential of liposomes. The 
hyperthermia looms to be an important means for modifying the target environment and 
increasing liposome delivery to tumors. For example, in animal models, it was observed that 
the heating to temperatures up to 41–43°C can increase the tumor microvascular pore size 
and accordingly increases its permeability to various substances (e.g., ferritin, antibodies, 
and liposomes), perhaps hyperthermia can disaggregate the endothelial cell cytoskeleton. 
For instance, in a human tumor xenograft murine model (SKOV-3), the extravasation of 100 
nm liposomes was not observed at 34°C, but it was seen after heating to 40°C (Kong et al., 
2001). In 2010, Bellavance et al reported on development of a novel cationic liposome 
formulation composed of DPPC:DC-Chol:DOPE:DHPE Oregon Green, which was shown to 
possesses efficient internalization and intracellular delivery to F98 and U-118 glioblastoma 
(GBM) cells in pH-sensitive manner. At which point, they suggested such liposomal 
formulation as a novel potent and efficient vehicle for cytosolic delivery of intracellular 
therapeutics such as chemotherapy agents to the glioblastoma (Bellavance et al., 2010). So 
far, various liposomal and polymeric formulations have been introduced as smart (thermo-
sensitive and/or pH sensitive) nanomedicines that can provide a controlled drug release in 
target tumors. In particular, the pH-sensitive nanosystems have been given greater attention 
since the pH targeting approach is regarded as a more general strategy than conventional 
specific tumor cell surface targeting approaches. In fact, the nanosystems display greater 
potential to overcome multidrug resistance of various tumors when they are combined with 
triggered release mechanisms by endosomal or lysosomal acidity plus endosomolytic 
capability – this important domain has been well reviewed recently, see (Lee et al., 2008).  
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In addition, little is known about impacts of metastatic disease on the BBB. Although the 
brain metastases respond to chemotherapy modalities, such responses are largely 
dependent upon condition of patients. For example, 14 patients with brain metastases from 
small cell lung cancer (SCLC) were treated with combination therapy of cyclophosphamide, 
doxorubicin, vincristine, and etoposide. Of the treated patients, 9 of 11 patients (82%) 
showed responses in their brain lesions, whereas 9 of 12 evaluated patients  (75%) had 
responses in their extracranial lesions (Lee et al., 1989). In another study, patients with SCLC 
and brain metastases were treated with cisplatin, ifosfamide, and irinotecan with rhG-CSF 
support. The response rate was 50% in brain lesions and 62% in extracranial primary or 
metastatic lesions (Fujita et al., 2000). The most studies for assessing leakiness of the BBB in 
human brain tumors appear to be the T1-weighted techniques (in particular, T1-weighted 
dynamic contrast-enhanced imaging). In fact, researchers implement this methodology 
using a 3D spoiled gradient acquisition steady-state technique that monitors contrast 
material accumulation over a few minutes rather than observing the first-pass phenomenon. 
The main advantages of this technique seem to be the relatively short imaging time, a need 
for only a single dose of contrast material, and availability of a large number of user-friendly 
analysis programs (Provenzale et al., 2005). 
10. Recent advancements for crossing BBB 
Selective functional presence of BBB makes brain delivery and targeting very challenging 
issue, for which various strategies have been developed, including different classes of 
nanomedicines. These novel strategies are largely dependent upon biological characteristics 
of BBB, and accordingly nanomedicines exploit endocytic pathways. Unfortunately, patients 
with primary brain tumors and brain metastases have a very poor prognosis. This is often 
exacerbated with low responses to chemotherapy attributed to BBB selective control on 
permeation of cytotoxic agents. Nanomedicines represent great promise in glioma therapy 
as they protect therapeutic agent and allow its sustained release even though tumor specific 
targeting paradigms with extensive intratumoral distribution must be developed for 
efficient delivery.  
Paclitaxel as an active agent against gliomas and various brain metastases is substrate of P-
gp efflux transporter, and thus it is pumped out of brain parenchyma. To tackle this issue, 
Koziara et al. developed novel cetyl alcohol/polysorbate NPs for encapsulation and 
delivery of anticancer agents such as paclitaxel (PX) to brain. They showed significant 
increase of paclitaxel in brain using such NPs because of the limited binding of PX to p-gp 
(Koziara et al., 2004). With an effort to evaluate the characteristics of an ultrasmall 
superparamagnetic iron oxides (USPIO) agent in patients with brain tumors and to correlate 
changes on MRI with histopathologic data collected systematically in all patients, Taschner 
et al. examined 9 patients with brain tumors before and 24 hr after administration of a 
USPIO at a dose of 2.6 mg Fe/kg. They witnessed USPIO-related changes of signal intensity 
in gadolinium-enhancing brain tumors in 7 patients. Upon such findings, they suggested 
that USPIO agents can offer complementary information useful to differentiate between 
brain tumors and areas of radiation necrosis (Taschner et al., 2005). Interestingly, in 2006, 
Wu et al. reported construction of a drug delivery vehicle with ability to target the 
epidermal growth factor receptor (EGFR) and its mutant isoform EGFRvIII. In their work, 
the EGFR targeting monoclonal antibody, cetuximab, was covalently linked to a 
Polyamidoamine (PAMAM) dendrimer containing the cytotoxic drug methotrexate. Using 
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the EGFR-expressing rat glioma cell line F98(EGFR), they showed that the bioconjugate 
retained its affinity for F98(EGFR) cells and the IC50 of the bioconjugate was 220 nmol/L. 
The bioconjugate in rats bearing i.c. implants of either F98(EGFR) or F98(WT) gliomas was 
determined 24 hr following convection enhanced delivery of (125)I-labeled complex, 
showing specific molecular targeting of the tumor. Based on such findings, they concluded 
that the antibody-drug bioconjugate is therapeutically useful approach in brain tumors (Wu 
et al., 2006). In 2009, Veiseh et al reported on development of an iron oxide nanoparticle 
coated with polyethylene glycol-grafted chitosan with ability to cross the BBB and target 
brain tumors in a genetically engineered mouse model. The nanoprobe was conjugated to a 
tumor-targeting agent, chlorotoxin, and a near-IR fluorophore. Using in vivo magnetic 
resonance, biophotonic imaging, and histologic and biodistribution analyses, they showed 
an innocuous toxicity profile induced by the nanoprobe, while it showed a sustained 
retention in tumors and suggested its application for the diagnosis and treatment of a 
variety of tumor types in brain (Veiseh et al., 2009). Using novel quaternary ammonium 
beta-cyclodextrin (QAbetaCD) NPs (with 65-88 nm diameter and controllable cationic 
properties), Gil et al reported successful delivery of doxorubicin (DOX) across the BBB. They 
showed that QAbetaCD NPs are not toxic to bovine brain microvessel endothelial cells 
(BBMVECs) at concentrations up to 500 g/mL. They also showed that the 
DOX/QAbetaCD complexes can kill U87 cells as effectively as DOX alone, while the 
QAbetaCD NPs completely protect BBMVECs from cytotoxicity of DOX. And as a result, it 
was suggested that the QAbetaCD NPs as safe and effective delivery system for anticancer 
agents such as DOX for brain tumors (Gil et al., 2009). Upon the of note tropism of 
mesenchymal stem cells (MSCs) for brain tumors, Roger et al exploited the MSCs as NP 
delivery vehicles, in which they used two types of NPs loaded with coumarin-6, i.e. poly-lactic 
acid NPs (PLA-NPs) and lipid nanocapsules (LNCs). They showed efficient internalization of 
the NPs into MSCs that were able to migrate toward an experimental human glioma model. 
They suggested MSCs as potential cellular carriers for delivery of NPs into brain tumors 
(Roger et al., 2010). In 2011, A dual-targeting drug carrier (PAMAM-PEG-WGA-Tf) was 
developed based on the PEGylated fourth generation PAMAM dendrimer with Tf and wheat 
germ agglutinin (WGA) on the periphery and DOX loaded in the interior (He et al., 2011). 
Having nanoscaled size (~ 20 nm), the PAMAM-PEG-WGA-Tf efficiently inhibited the growth 
rate of the C6 glioma cells, while it reduced the cytotoxicity of DOX to the normal cells. These 
researchers reported significantly increase and accumulation of DOX in the tumor site (due to 
the targeting effects of both Tf and WGA) and suggested that it could be used as a BBB 
penetrating agent with tumor targeting properties (He et al., 2011). 
11. Chapter summary  
Entry of blood circulating agents into brain is highly controlled by selectively functional 
presence of BBB. This makes brain drug delivery and targeting very intricate. Owing to 
unique biology of brain capillary endothelial cells, carrier and/or receptor mediated 
transport machineries of BBB can be exploited using smart pharmaceuticals. In the case of 
tumors such as glioma, use of intelligent molecular Trajan horses appears to provide a 
combined imaging-therapy as “theranostic” to ease brain drug delivery and targeting by 
simultaneous imaging techniques such as positron emission tomography (PET). In near 
future, it is expected new multifunctional “all in one” therapeutic to be translated into clinic 
to cure brain tumors in much more efficient manner. Such therapeutics may consist of 
homing device for targeting, imaging moiety for sensing/imaging, and therapeutic itself in a 
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vehicle that could be activated by outside/inside stimulation (pH, temperature, enzyme). To 
translate such fascinating molecular therapy into clinical use, however, we need to recruit 
several disciplines such as nanotechnology, biotechnology, biophotonics, engineering, 
biopharmaceutics and clinical expertise.  
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